95 related articles for article (PubMed ID: 25563560)
21. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Andersen CL; Bjørn ME; McMullin MF; Harrison C; Samuelsson J; Ejerblad E; Zweegman S; Fernandes S; Bareford D; Knapper S; Löfvenberg E; Linder O; Andreasson B; Ahlstrand E; Jensen MK; Bjerrum OW; Vestergaard H; Larsen H; Klausen TW; Mourits-Andersen T; Skov V; Thomassen M; Kruse T; Grønbæk K; Hasselbalch HC
Leuk Res; 2014 Jul; 38(7):816-21. PubMed ID: 24836761
[TBL] [Abstract][Full Text] [Related]
22. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
Chen G; Yang T; Gu Q; Ni XH; Zhao ZH; Ye J; Meng XM; Liu ZH; He JG; Xiong CM
Respirology; 2014 May; 19(4):608-15. PubMed ID: 24689969
[TBL] [Abstract][Full Text] [Related]
23. Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients.
Jaksch P; Taghavi S; Klepetko W; Salama M
J Thorac Cardiovasc Surg; 2014 Jul; 148(1):273-81. PubMed ID: 24685381
[TBL] [Abstract][Full Text] [Related]
24. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children.
Kyrgios I; Galli-Tsinopoulou A; Stylianou C; Papakonstantinou E; Arvanitidou M; Haidich AB
Metabolism; 2012 Apr; 61(4):562-8. PubMed ID: 22036069
[TBL] [Abstract][Full Text] [Related]
25. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
Mylin AK; Abildgaard N; Johansen JS; Heickendorff L; Kreiner S; Waage A; Turesson I; Gimsing P;
Leuk Lymphoma; 2015; 56(9):2650-9. PubMed ID: 25573204
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma multiforme classified as mesenchymal subtype.
Koev IG; Feodorova YN; Kazakova MH; Staykov DG; Kitov BD; Sarafian VS
Folia Med (Plovdiv); 2014; 56(3):215-9. PubMed ID: 25434080
[TBL] [Abstract][Full Text] [Related]
27. YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment.
Lai T; Chen M; Deng Z; L Y; Wu D; Li D; Wu B
BMC Pulm Med; 2015 Jan; 15():1. PubMed ID: 25578181
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.
Fan JT; Si XH; Liao Y; Shen P
Arch Gynecol Obstet; 2013 Jan; 287(1):111-5. PubMed ID: 22945838
[TBL] [Abstract][Full Text] [Related]
29. Association between serum YKL-40 level and dysglycemia in cystic fibrosis.
Bouvet GF; Maignan M; Arslanian E; Coriati A; Rabasa-Lhoret R; Berthiaume Y
Cytokine; 2015 Feb; 71(2):296-301. PubMed ID: 25497736
[TBL] [Abstract][Full Text] [Related]
30. Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population.
Aguilera E; Serra-Planas E; Granada ML; Pellitero S; Reverter JL; Alonso N; Soldevila B; Mauricio D; Puig-Domingo M
Cardiovasc Diabetol; 2015 Sep; 14():121. PubMed ID: 26382922
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
32. Serum markers in early-stage and locally advanced melanoma.
Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
[TBL] [Abstract][Full Text] [Related]
33. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
Özdemir E; Çiçek T; Kaya MO
Urol J; 2012; 9(3):568-73. PubMed ID: 22903479
[TBL] [Abstract][Full Text] [Related]
34. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
[TBL] [Abstract][Full Text] [Related]
35. Serum YKL-40/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome.
Bakırcı EM; Ünver E; Değirmenci H; Kıvanç T; Günay M; Hamur H; Büyüklü M; Ceyhun G; Topal E; Çoban TA
Turk Kardiyol Dern Ars; 2015 Jun; 43(4):333-9. PubMed ID: 26142786
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
Kemik P; Saatli B; Yıldırım N; Kemik VD; Deveci B; Terek MC; Koçtürk S; Koyuncuoğlu M; Saygılı U
Gynecol Oncol; 2016 Jan; 140(1):64-9. PubMed ID: 26607777
[TBL] [Abstract][Full Text] [Related]
37. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
[TBL] [Abstract][Full Text] [Related]
38. YKL-40 protein correlates with the phenotype of asthma.
Specjalski K; Chełmińska M; Jassem E
Lung; 2015 Apr; 193(2):189-94. PubMed ID: 25663327
[TBL] [Abstract][Full Text] [Related]
39. YKL-40 in Asthma and its correlation with different clinical parameters.
Saba M; Sharif MR; Akbari H; Nikoueinejad H; Ramazani Jolfaii M
Iran J Allergy Asthma Immunol; 2014 Aug; 13(4):271-7. PubMed ID: 24659163
[TBL] [Abstract][Full Text] [Related]
40. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
